5.10Open5.10Pre Close0 Volume0 Open Interest46.50Strike Price0.00Turnover0.00%IV2.67%PremiumDec 6, 2024Expiry Date3.76Intrinsic Value100Multiplier2DDays to Expiry1.34Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma14.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
lets gooooooo
No comment yet